Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00311753 |
Acutely ill immobilized patients are at a high risk for thromboembolic events including deep venous thrombosis or pulmonary embolism. Unfractionated heparin (UFH) and low molecular weight heparins (LMWH) are thought to be effective in preventing thromboembolic events. This study is designed to provide efficacy and safety data for thromboprophylaxis with the LMWH certoparin in comparison to thromboprophylaxis with UFH in acutely ill non-surgical patients.
Condition | Intervention | Phase |
---|---|---|
Embolism |
Drug: low molecular weight heparin |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | An Open-Label Comparison of the Efficacy and Safety of the Low-Molecular-Weight Heparin (3000 U Anti-Xa Once Daily) With Unfractionated Heparin for the Prevention of Thromboembolic Complications in Acutely Ill Non-Surgical Patients |
Enrollment: | 342 |
Study Start Date: | February 2006 |
Primary Completion Date: | October 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Study ID Numbers: | CMEX839BDE02 |
Study First Received: | April 4, 2006 |
Last Updated: | November 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00311753 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
heparin, thromboprophylaxis, medical patients, acutely ill Acutely ill non surgical patients Immobilization |
Body Weight Calcium, Dietary Embolism and Thrombosis Embolism Heparin, Low-Molecular-Weight |
Vascular Diseases Heparin Thrombosis Calcium heparin |
Fibrin Modulating Agents Anticoagulants Molecular Mechanisms of Pharmacological Action Therapeutic Uses Hematologic Agents |
Fibrinolytic Agents Cardiovascular Diseases Cardiovascular Agents Pharmacologic Actions |